Location: US Remote 

Overview

Current Health helps cancer centers move CAR-T and bispecific care out of the hospital. Some of our partners have moved as much as 90% of their CAR-T to outpatient but most centers are still far from that.

This role will help centers to close the gap. Working in-market with our health-system partners, you will find what keeps eligible patients inpatient and remove it, clinically, operationally, and financially, alongside each program’s physicians and leaders.

Responsibilities

• Build peer-level relationships with the people who decide where a CAR-T patient is infused: cell therapy medical directors and attendings, program managers and coordinators, APPs, pharmacy, nursing leadership, and hospital finance and managed care.
• Audit every inpatient CAR-T infusion and bispecific start at assigned accounts, tie each to the barrier that kept it inpatient (product toxicity profile, patient risk, caregiver, lodging or distance, payer authorization, trial protocol, bed policy, physician preference), and remove the largest barriers first.
• Care models. Co-design and launch outpatient and hybrid models for CAR-T, bispecifics, and other T-cell–redirecting therapies: fully outpatient, outpatient infusion with admission at first fever, early discharge with remote monitoring, and outpatient step-up dosing.
• With each program’s medical director, co-develop patient-selection criteria, SOPs and order sets, 24/7 triage, and direct-admit and bed-backup pathways that bypass the ED. Bring older protocols in line with the June 2025 FDA label changes.
• With hospital finance, model inpatient vs. outpatient vs. early-discharge economics by payer and product (e.g., DRG 018 vs. OPPS, Medicare’s 3-day payment window, bed-days freed for transplant and other admissions), and present the case to administration.
• Payer access. Work with managed care and financial clearance to remove site-of-care barriers: prior authorizations, single-case agreements, and contracts written on the assumption of inpatient infusion.
• Patient logistics. Solve the non-clinical blockers that keep eligible patients inpatient (caregiver coverage, lodging near the center, transportation) with navigation, social work, and manufacturer support programs.
• Measure and publish unplanned admissions, ICU transfers, time to admission, length of stay, and bed-days returned. Help customer clinicians present results (Tandem Meetings, ASH) and host peer site visits.
• Own a growth plan with targets for each account (outpatient share of eligible infusions, enrolled patients, patient-days) and add adjacent use cases: bispecifics, autologous transplant, post-discharge monitoring, and hand-back to referring oncologists.
• Field insight. Bring workflow gaps and product needs back to Current Health’s product and clinical teams.

Experience Required

• 5+ years in cellular therapy, including direct responsibility for launching or scaling an outpatient or hybrid CAR-T program at a FACT-accredited center (e.g., cell therapy program manager or director, cell therapy APP, nurse manager or coordinator).
• Active RN, NP, PA, or PharmD license; BMT or oncology certification (BMTCN, AOCNP, BCOP) preferred.
• Expert in toxicity grading and management and in each product’s toxicity profile and timing and how those drive outpatient patient selection.
• Working knowledge of FACT-JACIE standards for cell therapy programs, accreditation inspections, and manufacturer treatment-center qualification.
• Fluent in cell therapy reimbursement (MS-DRG 018, OPPS and HCPCS Q-codes, the Medicare 3-day window, commercial case rates and carve-outs, prior authorization), well enough to build a business case a CFO will accept.
• Track record of leading change across physicians, nursing, pharmacy, finance, and IT without direct authority, including launching at least one new service line or care model end to end.
• Travel required 40% of the time.